ASB Consultores LLC Has $336,000 Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

ASB Consultores LLC decreased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.3% during the 3rd quarter, HoldingsChannel reports. The fund owned 3,110 shares of the medical equipment provider’s stock after selling 175 shares during the period. ASB Consultores LLC’s holdings in Zimmer Biomet were worth $336,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. Private Advisor Group LLC grew its holdings in shares of Zimmer Biomet by 2.2% during the first quarter. Private Advisor Group LLC now owns 10,846 shares of the medical equipment provider’s stock worth $1,431,000 after purchasing an additional 236 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Zimmer Biomet by 7.6% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 52,214 shares of the medical equipment provider’s stock worth $6,668,000 after buying an additional 3,682 shares during the period. Fidelis Capital Partners LLC bought a new stake in Zimmer Biomet during the 1st quarter worth approximately $69,000. Nordea Investment Management AB increased its position in Zimmer Biomet by 11.4% in the 1st quarter. Nordea Investment Management AB now owns 15,154 shares of the medical equipment provider’s stock valued at $2,006,000 after acquiring an additional 1,551 shares during the period. Finally, Financial Counselors Inc. raised its stake in shares of Zimmer Biomet by 5.6% during the first quarter. Financial Counselors Inc. now owns 5,006 shares of the medical equipment provider’s stock valued at $661,000 after acquiring an additional 264 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH opened at $108.41 on Tuesday. The stock’s 50 day moving average is $106.83 and its 200-day moving average is $110.66. Zimmer Biomet Holdings, Inc. has a twelve month low of $101.47 and a twelve month high of $133.90. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. The firm has a market capitalization of $21.58 billion, a price-to-earnings ratio of 20.61, a PEG ratio of 1.97 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.74. The firm had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The business’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.65 EPS. Sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, October 31st. Stockholders of record on Monday, September 30th were given a dividend of $0.24 per share. The ex-dividend date was Monday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.89%. Zimmer Biomet’s dividend payout ratio is presently 18.25%.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ZBH. TD Cowen reduced their price objective on shares of Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating on the stock in a research note on Friday, September 6th. Robert W. Baird reduced their price target on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. Wells Fargo & Company lifted their price objective on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Royal Bank of Canada upped their target price on Zimmer Biomet from $120.00 to $125.00 and gave the company an “outperform” rating in a report on Monday. Finally, Wolfe Research initiated coverage on shares of Zimmer Biomet in a report on Tuesday, September 10th. They set a “peer perform” rating for the company. Two analysts have rated the stock with a sell rating, twelve have given a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $124.11.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.